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Comorbidity with anxiety or depression is common in patients with Inflammatory
Bowel Disease (IBD) as Crohn Disease (CD) and Ulcerative Colitis (UC). Data suggest
that the cognitive construct of alexithymia has high prevalence in people suffering
from anxiety and mood disorders and even in people with IBD. Most studies
have investigated mainly anxiety and depression, considering IBD population as a
homogeneous group of patients. Little evidence shows the impact of alexithymia
on the course of IBD. We evaluated a broad spectrum of psychopathological
symptoms and alexithymia levels in a group of outpatients affected by IBD in clinical
remission, comparing CD and UC and investigating the relationship with clinical and
socio-demographic variables. One hundred and seventy IBD outpatients were screened
by using the Hospital Anxiety Depression Scale (HADS), the Self-report Symptom
Inventory-90-Revised (SCL-90-R) and the Toronto Alexithymia Scale (TAS-20). A high
prevalence of anxious and depressive symptoms (42.35 and 25.8% respectively)
together with alexithymia (31.76%) was confirmed. CD patients experienced high
levels of depression (HADS Depression 35.2% p = 0.034; SCL-90-R mean 1.39
p < 0.001), somatisation (SCL-90-R mean 1.04 p < 0.001), obsessive-compulsive
symptoms (SCL-90-R mean 1.2 p < 0.001), and global severity (SCL-90-R mean
1.15 p < 0.001). There is no statistical difference in the prevalence of alexithymia in
both subpopulations. The levels of alexithymia are correlated to the levels of anxiety
(HADS Anxiety rs = 0.516 p < 0.001), depression (HADS Depression rs = 0.556
p < 0.001; SCL-90-R rs = 0.274 p = 0.001), somatisation (SCL-90-R rs = 0.229
p = 0.005), obsessive-compulsive symptoms (SCL-90-R rs = 0.362 p < 0.001),
and global severity (SCL-90-R rs = 0.265 p = 0.001). Furthermore, alexithymia
is associated with a delay of diagnosis of IBD, poly-therapies and greater IBD
extension. Older age, female gender, greater IBD extension, surgery, and delay of
diagnosis seem to be related to a high prevalence of psychopathological symptoms
such as anxiety, depression, somatisation, and obsessive-compulsive symptoms.
Viganò et al. Alexithymia and Psychopathology in IBD
Psychopathological symptoms and high levels of alexithymia are frequent in IBD patients
and seem to be related to a high risk of poor clinical outcome. CD patients could
be considered at higher risk of mental comorbidity. A more comprehensive psychiatric
assessment, including alexithymia, and an integrated treatment of underlying conditions,
must be taken into account in order to improve the global prognosis of the disease.
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INTRODUCTION
Chronic Inflammatory Bowel Disease (IBD) mainly represented
by Crohn Disease (CD) and Ulcerative Colitis (UC), are
characterized by the occurrence of chronic inflammation with an
unpredictable evolution distinguished by flares and remissions.
While inflammation in CD can involve the entire gastrointestinal
tract (1), the inflammation in UC is localized at the colon
and rectum level only. The incidence of IBD in Italy is
comparable with that reported in Northern Europe and has
gradually increased in the last decades (9.6/100.000 for UC
and 3.4/10.000 for CD) (2). Patients who suffer from IBD
frequently manifest extra-intestinal complications and need to
undergo surgical conservative therapy or resective surgery,
with different procedures between CD and UC (3, 4). The
IBD pathogenesis is multifactorial: environmental factors can
give rise to an inappropriate and excessive intestinal immune
response in genetically-predisposed subjects and in the presence
of dysbiosis of the gut microbiota (5). The chronic nature of
IBD and its frequent onset in early adulthood (15–30 years
old) (6) cause severe stress and worsening of quality of life
(4, 7). Multiple flares, low social support and high stress
levels, as well as psychiatric comorbidities, usually worsen the
quality of life (8) and increase the risk of mental distress
when compared to the general population (9, 10). A substantial
quantity of data showed the comorbidity among anxiety,
depression and IBD, whose prevalence is estimated to be
around 30% in patients in clinical remission, while it reaches
up to 60–80% during the active phase of the disease (11–
13).
Several studies identified the risk factors causing anxiety and
depression in IBD. The female gender (14), old age, high levels
of perceived stressed influenced by negative coping strategies
(15, 16), active or severe diseases (17), surgical complications
and low-level of perceived social support (18, 19) seem to be the
main risk factors for the development of psychiatric symptoms
in IBD patients (20–22). The presence of anxious or depressive
symptoms is associated with reduced treatment compliance (23),
increase in disability (24), and mortality (25).
Epidemiological studies highlighted a high prevalence of
specific psychological functions such as alexithymia among
patients suffering from anxiety disorders (26), obsessive-
compulsive disorders (27), and mood disorders (28, 29), even in
patients affected by chronic and immune-mediated pathologies
with somatic symptoms (30).
Alexithymia is a construct characterized by specific
cognitive traits like the difficulty in identifying, describing
and differentiating emotions, with a reduction of imaginative
processes (poverty of imagination and fantasy) and with a
cognitive style oriented to the external reality and to operative
thinking (31). The prevalence of alexithymia in patients
suffering from depressive disorders reaches 33.3%, while it
is around 42% in patients suffering from anxiety disorders
(32). These rates of comorbidity suggest a correlation between
the phenomena; data assume that alexithymia may interfere
with response to treatment in depressed and anxious patients
(33). Even in IBD patients the prevalence is about 35% (34);
it is well-known that alexithymia is closely related to clinical
severity of gastrointestinal functional disease (35). Some studies
identify alexithymia as a stable construct not influenced by the
clinical evolution of gastrointestinal pathologies (36) with a
negative impact on the subjective health status of IBD patients
(37).
To date, most studies have mainly investigated the prevalence
of anxiety and depression considering IBD as a homogeneous
group of patients (38); little data considered the two sub-
populations of UC and CD patients independently (12, 13)
and evaluated the association between IBD and specific
psychological functions (39). However, so far no study
has evaluated a broader spectrum of psychopathological
symptoms. This evidence suggests that psychopathological
comorbidity could be under-recognized and under-diagnosed
in clinical practice with standardized patterns of care, which
do not consider the possible specific different needs and
personal outcomes. Indeed, a recent survey identified
that in the US only 36% of patients affected by IBD and
depressive symptoms actually received professional support
(40).
The aim of this study is to evaluate a broad spectrum
of psychopathological symptoms, psychological distress, and
alexithymia levels in a group of Italian outpatients affected
by IBD in clinical remission, analyzing possible differences
between the two subpopulations of patients (CD and UC)
and investigating possible links to specific clinical and socio-
demographic variables.
MATERIALS AND METHODS
Participants
In this study, a consecutive series of IBD outpatients was
recruited from January 2016 to September 2017 and regularly
followed-up at the IBD Centre of the Gastroenterology
department and IBD Unit of the local public healthcare facility
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TABLE 1 | Inclusion/exclusion criteria.
Inclusion criteria:
• Diagnosis of Crohn’s Disease of Ulcerative Colitis in clinical remission
(Crohn’s Disease Activity Index (CDAI) < 150, Mayo score 0–2).
• Age between 18 and 65 years old
• Informed consent given by the patient to take part in the study.
Exclusion criteria:
• Crohn’s Disease or Ulcerative Colitis in active phase
• Previous psychiatric diagnosis
• IQ < 70
• Active pregnancy, cognitive impairment, documented head trauma,
concomitant neurological, or oncologic pathologies
• Comorbidity with alcohol or substance abuse or severe personality disorder
ASST-Fatebenefratelli-Sacco University Hospital in Milan, Italy.
All patients met the inclusion and exclusion criteria reported in
Table 1.
Study Design
The eligible sample was screened considering the following
variables:
a) Socio-demographic and clinical variables through a
standardized survey (diagnosis, gender, age, marital
status, level of education, employment status, therapy,
family history of IBD, age at onset of IBD symptoms, age at
diagnosis, diagnostic delay, disease extension, surgery).
b) Psychological distress screening through theHospital Anxiety
and Depression Scale (HADS) (Cronbach’s alpha 0.83 for
HADS-Anxiety, 0.82 for HADS-Depression) (41, 42).
c) Psychiatric symptomatology assessment through the Self-
report Symptom Inventory Revised (SCL-90-R) (Cronbach’s
alpha 0.96) (43, 44).
d) Alexithymia levels evaluation through the Toronto
Alexithymia Scale (TAS-20) (Cronbach’s alpha 0.81)
(45, 46).
Statistical Analysis
The distribution of the obtained data was evaluated, and resulted
in having non-parametric characteristics. For the anxious-
depressive symptomatology-screening test (HADS), for the
psychiatric symptoms evaluation test (SCL-90-R), and for the
test concerning the alexithymia dimension (TAS-20) the mean
scores were evaluated in the total population of patients and
in the sub-populations of patients affected by UC and CD.
As far as the HADS and TAS-20 scales are concerned, the
prevalence of resulting positive according to the decisional cut-
off values for each sub-scale was also considered (HADS score
≥ 8 for the anxiety or depression scale, TAS-20 score ≥ 50,
including also borderline patients) (42, 47). The values of the
UC and CD groups were compared using the Wilcoxon-Mann-
Whitney test, considering values of p < 0.01 as significant. The
relation between symptomatology, alexithymia level, and socio-
demographic variables were studied through the Spearman’s
Rho correlation (rs), considering values p < 0.01 as significant,
TABLE 2 | Socio-demographic and clinical variables.
Diagnosis,
n (%)
Crohn’s disease (CD): 68 (40%)
Ulcerative colitis (UC): 102 (60%)
Gender,
n (%)
Male: 94 (55.3%)
Female: 76 (44.7%)
Age (years) mean
(± SD)
47.1 (±12.03)
Marital status,
n (%)
Married: 80 (47.06%)
Single: 67 (39.41%)
Widowed: 15 (8.82%)
Divorced: 8 (4.71%)
Level of education,
n (%)
High school: 85 (50%)
Middle school: 40 (23.53%)
University degree: 40 (23.53%)
Elementary school: 5 (2.94%)
Employment status,
n (%)
Employed: 105 (61.76%)
Self-employed: 33 (19.42%)
Unemployed: 14 (8.23%)
Pensioner: 13 (7.65%)
Student: 5 (2.94%)
Therapy,
n (%)
NSAID: 105 (61.76%)
Immunosuppressive medications: 38 (22.36%)
TNF inhibitor: 14 (8.23%)
Methotrexate: 5 (2.94%)
Poly-therapy: 8 (4.71%)
Family history of IBD,
n (%)
Yes: 35 (20.59%)
No: 135 (79.41%)
Age at onset of IBD
symptoms (years) mean
(± SD)
29.72 (±10.48)
Age at diagnosis
(years) mean
(± SD)
30.3 (±10.02)
Diagnostic delay (months)
mean (± SD)
11.8 (±30.54)
Extension of IBD,
n (%)
UC CD
Proctitis: 8 (7.8%) L1: 4 (5.9%)
Left side colitis: 32
(31.4%)
L2: 40 (58.8%)
L3: 24 (35.3%)
Subtotal or
pancolitis: 62
(60.8%)
L4: 0
Surgery,
n (%)
UC CD
Yes 20 (19.6%) 38 (55.9%)
No 82 (80.4%) 30 (44.1%)
while values of p < 0.05 were considered as significant
in some cases of data considered of clinical interest. The
statistical analysis was carried out by using the SPSS program,
version 24.
RESULTS
We sequentially recruited 170 patients who met the study
inclusion criteria; 68 patients suffering from CD and 102
suffering from UC. The related socio-demographic and clinical
characteristics are described in Table 2.
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Prevalence of Anxious and Depressive
Symptoms and General
Psychopathological Symptoms
Considering the total population undergoing screening, around
42.35% of patients resulted having positive scores for anxious
symptoms and 25.8% for depressive symptoms. The prevalence of
anxiety was comparable between the two groups (42.15% in UC
and 42.63% in CD) while the prevalence of depressive symptoms
was greater in CD patients (35.2% vs. 20.5% p= 0.034).
Crohn’s disease patients had greater scores of somatisation
(mean 1.04; ± SD 0.92 p < 0.001), obsessive-compulsive
symptoms (mean 1.2; ± SD 1.17 p < 0.001), depression (mean
1.39;± SD 1.09 p < 0.001), and global severity index (mean 1.15;
± SD 0.75 p < 0.001), as shown in Table 4.
Alexithymia Levels in the Sample
The prevalence of alexithymia in the total sample is 31.76%,
36.8% in CD and 28.43% in UC patients, with no statistical
differences between two groups (p > 0.05) (Table 3).
The mean values for alexithymia in the global population
were significant when taking into consideration the dimensions
defined as “externally-oriented cognitive style” (mean 19.89± SD
7.48) and “difficulty in identifying feelings” (mean 15.12 ± SD
7.23) (Table 5).
Significance in mean values in UC patients, in both the above
mentioned dimensions, was confirmed as shown in the Table 4;
the significant scores for CD patients were found only for the
“externally-oriented cognitive style” dimension (mean 21.45 ±
SD 8.98) and the score for “difficulty in identifying feelings”
reaches a mean of 14.73 (± SD 7.65). No significant statistical
differences between the two groups were observed (p > 0.05).
Correlations Between Psychopathology,
Alexithymia, Socio-Demographic Variables,
and CD/UC Variables (Table 6)
Considering the socio-demographic variables, high levels of
anxiety were more frequently reported in women (HADS anxiety
rs 0.18; p = 0.02), while significant levels of depression were more
common in older patients (HADS depression rs 0.179; p = 0.021).
A positive correlation was found between IBD-type (CD > UC)
and somatisation (rs 0.568; p < 0.001) and obsessive-compulsive
symptoms (rs 0.506; p < 0.001), depression (rs 0.678; p < 0.001),
anxiety (rs 0.550; p < 0.001), and global severity index (rs 0.712;
p < 0.001).
Furthermore, the extension of IBD positively correlates
with somatisation symptoms (rs 0.32; p < 0.001), obsessive-
compulsive symptoms (rs 0.402; p < 0.001), depression (rs 0.471;
p < 0.001), anxiety (rs 0.389; p < 0.001), and global severity
symptoms (rs 0.456; p < 0.001). Diagnostic delay and previous
surgical treatment were positively associated with depressive
symptoms in the HADS screening (rs 0.294; p = 0.002—rs
0.192; p = 0.016) and in the assessment with SCL-90-R (rs
0.252; p = 0.012—rs 0.295; p < 0.001), somatisation symptoms
(rs 0.306; p = 0.002—rs 0.168; p = 0.043), anxiety (rs 0.244;
p = 0.015—rs 0.248; p = 0.001), and global severity index (rs
0.251; p = 0.012—rs 0.267; p = 0.001). A history of surgery
for IBD was associated with a higher prevalence of obsessive-
compulsive symptoms (rs 0.263; p= 0.001).
TABLE 3 | Prevalence of positive tests (HADS Anxiety ≥ 8, HADS Depression ≥ 8, TAS – 20 total score ≥ 50 ) in a comparative analysis between UC and CD using
Wilcoxon-Mann-Whitney test (p < 0.05).
Total UC CD U W Z P
HADS Anxiety % (n) 42.35% (72) 42.15% (43) 42.63% (29) 3397.5 8753.5 −0.197 0.843
HADS Depression % (n) 25.8% (45) 20.50% (21) 35.2% (24) 2958 8211 −2.123 0.034
TAS-20 total score % (n) 31.76% (54) 28.43% (29) 36.80% (25) 3222.5 8373.5 −1.031 0.303
TABLE 4 | Psychopatological and alexithymia scores analysis in sub-group UC/CD and comparative analysis using the Wilcoxon-Mann-Whitney test (p < 0.01).
UC CD
Mean ± SD Mean ± SD U W Z P
HADS Anxiety 7.15 4.22 7.2 7.15 3206 8156 −0.04 0.97
HADS Depression 4.9 3.5 5.8 5.8 2838.05 7788.5 −1.28 0.2
SCL-90-R somatisation 0.82 0.7 1.04 0.92 857 4685 −7.26 <0.001
SCL-90-R obsessive compulsive 0.91 0.71 1.2 1.17 1068.5 4895.5 −6.466 <0.001
SCL-90-R depression 0.83 0.75 1.39 1.09 544 4372 −8.439 <0.001
SCL-90-R global severity index 0.7 0.55 1.15 0.75 453 4281 −8.778 <0.001
TAS-20 “difficulty identifying feelings” 15.41 6.9 14.73 7.65 114.55 5027.5 −0.95 0.34
TAS-20 “difficulty describing feelings” 9.87 4.18 10 4.33 3006.5 5284.5 −0.03 0.98
TAS-20 “externally oriented cognitive style” 18.69 5.88 21.45 8.98 2489.5 6584.5 −1.868 0.062
TAS-20 total score 44.1 13.66 45.9 15.06 2878 6973 −0.486 0.627
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TABLE 5 | Psychopatological and alexithymia scores analysis in the IBD patients
group.
Mean ± SD
HADS Anxiety 7.17 4.34
HADS Depression 5.26 3.82
SCL-90-R somatisation 0.87 0.76
SCL-90-R obsessive compulsive 0.97 0.82
SCL-90-R depression 0.94 0.85
SCL-90-R global severity index 0.78 0.62
TAS-20 “difficulty identifying feelings” 15.12 7.23
TAS-20 “difficulty describing feelings” 9.93 4.23
TAS-20 “externally-oriented cognitive style” 19.89 7.48
TAS-20 total score 44.87 14.26
The total values of alexithymia on the TAS-20 scale had a
positive correlation with diagnostic delay (rs 0.213; p = 0.033),
utilization of IBD-specific poly-therapies (rs 0.200; p= 0.01), and
IBD extension (rs 0.16; p= 0.05).
The depressive symptoms evaluated both through the HADS
scale (rs 0.556; p < 0.001) and the SCL-90-R scale (rs 0.274;
p = 0.001), together with anxiety (rs 0.516; p < 0.001),
somatisation symptoms (rs 0.229; p = 0.005), obsessive-
compulsive symptomatology (rs 0.362; p < 0.001), and general
severity index (rs 0.265; p = 0.001) correlated positively with the
global alexithymia level.
DISCUSSION
In our outpatient sample, although made of clinically remitted
IBD patients, a high prevalence of anxious, depressive symptoms,
and alexithymia was confirmed, according to the several data in
literature (34, 48–50).
The study of the two sub-populations brings out differences
in the psychopathologic phenotype. Even while manifesting
similar levels of anxiety, patients affected by CD are usually
more severe than those with UC, manifesting depressive
symptoms with somatisations and symptoms on the OC
spectrum (control, rumination). The close relation between
anxious-depressive symptoms and IBD is presently explained
in the emerging theories of “gut-brain axis” dysfunction (51,
52). The presence of an alteration of the immune system
in pro-inflammatory sense involves an alteration of the
micro-anatomy and the gut microbiota (53), promoting the
development of a neuro-inflammation, with a modification of
synaptic plasticity and neuronal functioning (54, 55). Overall,
findings seem to confirm data emerging from a recent meta-
analysis showing correlation between depressive symptoms
and the negative progression of the disease, particularly in
CD patients, who are more likely to suffer from depression
compared with UC patients (56). The correlation between
the greater extension of the disease and psychopathological
severity reinforces the already-discussed differences relative
to the group of patients suffering from CD. The evidence
of correlation between depressive symptoms and surgical
interventions (57, 58) was confirmed and was shown to
TABLE 6 | Correlation between socio-demographic and clinical variables and
scores of rating scales using Spearman’s correlation (p <0.05).
Rho
Spearman
P
Age HADS Depression 0.179 0.021
Gender (F) HADS Anxiety 0.18 0.02
Diagnosis
(CD)
SCL-90-R somatisation 0.568 <0.001
SCL-90-R obsessive compulsive 0.506 <0.001
SCL-90-R depression 0.678 <0.001
SCL-90-R anxiety 0.550 <0.001
SCL-90-R global severity index 0.712 <0.001
IBD extension SCL-90-R somatisation 0.32 <0.001
SCL-90-R obsessive compulsive 0.402 <0.001
SCL-90-R depression 0.471 <0.001
SCL-90-R anxiety 0.389 <0.001
SCL-90-R global severity index 0.456 <0.001
TAS-20 total score 0.16 0.05
Delay of
diagnosis
HADS Depression 0.294 0.002
SCL-90-R somatisation 0.306 0.002
SCL-90-R depression 0.252 0.012
SCL-90-R anxiety 0.244 0.015
SCL-90-R global severity index 0.251 0.012
TAS-20 total score 0.213 0.033
Surgery HADS Depression 0.192 0.016
HADS Anxiety 0.276 0.007
SCL-90-R somatisation 0.168 0.043
SCL-90-R obsessive compulsive 0.263 0.001
SCL-90-R depression 0.295 <0.001
SCL-90-R anxiety 0.248 0.001
SCL-90-R global severity index 0.267 0.001
Poly-therapy TAS-20 total score 0.2 0.01
Level of
Alexithymia
(TAS 20 total
score)
HADS Anxiety 0.516 <0.001
HADS Depression 0.556 <0.001
SCL-90-R somatisation 0.229 0.005
SCL-90-R obsessive compulsive 0.362 <0.001
SCL-90-R depression 0.274 0.001
SCL-90-R global severity index 0.265 0.001
be more frequent in patients of CD, in comparison to
those affected by UC, causing worse effects on the quality
of life. These symptoms could explain the greater use of
antidepressant medications in patients suffering from CD (59).
Another significant datum regards the impact of diagnostic
delay on psychiatric symptoms: in the sample examined, it
seems to overlap previous data (60). The beginning of an
adequate therapeutic process might constitute a factor of
important psycho-physic stress with a subsequent impact on the
symptomatological level. In the same way, the already-evident
correlation between anxiety symptoms vs. female gender and
depressive symptoms vs. old age had been already highlighted in
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analogous studies dedicated to the populations affected by IBD
(61).
The studies of the prevalence of alexithymia in patients
suffering from chronic diseases (62) suggest a close
relationship with anxious and depressive clinical features.
A significant presence of alexithymia can be identified
also in patients from the sample affected by IBD, with no
significant difference between the two groups of patients.
The global level of alexithymia and all the dimensions of
the construct correlate with a greater severity of psychiatric
symptomatology, especially in the already-significant areas of
depression, anxiety, somatisation, and obsessive-compulsive
symptoms.
The association between alexithymia and obsessive-
compulsive symptoms is well-known (63, 64). Some studies
identified alexithymic construct as an endo-phenotype
associated with pure obsessions (in particular “difficulty in
describing emotions”) and hoarding and checking compulsions
(27). In alexithymic patients, the OC symptoms would
configure as maladaptive coping strategies for negative
emotions that the patient is not able to comprehend
and elaborate on. Furthermore, in a recent publication
Filipovic et al. (65) suggest that it would be desirable to
deepen the possible comorbidity with C-cluster personality
traits in patients affected by IBD (which included the
obsessive-compulsive personality disorder), underlining
some evidence already pointed out in the case of other chronic
diseases.
The presence of somatic symptoms in the general population
of alexithymic patients is well known and is basically associated
to a worsening of painful syndromes (66, 67) and also to a
worse condition in the forms of functional intestinal syndromes
(68). The presence of “difficulty in identifying emotions” and
“externally-oriented thinking” are associated with a reduced
quality of life with a high correlation to anxious and depressive
symptoms, somatisations, and reduced social functioning (69–
71). From our data, alexithymia is also associated with a
broader extension of gastrointestinal involvement and to a
longer duration of undiagnosed pathology, which, as already
seen, are in turn associated with a greater symptomatological
severity. This evidence could be explained by the “stress-
alexithymia hypothesis,” according to which elevated levels of
alexithymia are associated to an immune system alteration
in a pro-inflammatory sense (72). As already discussed, a
higher level of acute-phase proteins may predispose patients
to neuro-inflammation mediated psychiatric symptoms while,
on the other hand, they could worsen the course of the
gastrointestinal pathology. The alexithymic patients could be
unable to express the suffering related to the onset of the
disease, favoring the delay of the diagnosis. Moreover, the
alexithymic patients examined are predisposed to the use of
poly-therapies: this is likely, as these are patients who reached
a clinical remission after a long period of treatments in which
mono-therapies had failed, and can thus be defined as a
population of patients who is poorly responsive to medical
treatments.
Because alexithymia is a mental state denoting the inability to
identify emotions at a cognitive level, one hypotesis is that IBD
patients expressing high levels of alexithymia could misattribute
autonomic symptoms of anxiety (for example diarrhea and
abdominal pain) to that of IBD.
As described above and in a previous study (73), there are no
differences in alexithymia levels between CD and UC patients,
suggesting that this cognitive construct could be a common trait
that is globally oriented to worse mental health and poor clinical
outcome, leading patients to communicate their distress through
somatic symptoms rather than verbal contents.
ETHICS AND DISSEMINATION
The actual scientific evidence, within which the resulting data
are convincingly placed, increasingly underline the necessity
for a screening (74, 75) for psychiatric symptoms in patients
suffering from IBD, especially for CD patients. The early
identification of subjects with significant symptoms must be
taken into account to activate adequate treatment processes
(76, 77) in the perspective that those who do not receive
adequate treatment might be at higher risk of relapses and a
more aggressive form of the disease (78). In order to implement
the psychological and psychiatric support and treatment of IBD
patients, the “Ge.Co—Gastroenterologist collaboration project”
has been active in our Hospital since 2016. This project
includes different professionals interacting to create an integrated
exchange of competences. Patients can therefore take advantage
of gastroenterological, surgical together with psychiatric check-
ups, as well as psychological counseling with cognitive-behavioral
orientation, for the most part based on the mindfulness
approach (79). In our experience, in less than 2 years the
GE.Co Project has involved about 50 patients which have been
receiving both pharmacological and psychological treatment.
Our further goal is to extend participation in the project to
the greatest number of IBD patients, in order to improve the
diagnostic process in order to recognize specific anxiety or
mood disorders according to DSM5 criteria and to begin prompt
treatment.
A limitation of this study is the lack of data regarding
possible risk factors for depression and anxiety, such as
life events and patients’ socioeconomic level, and the
effect of these factors in relation to compliance with the
treatments. Furthermore, this study is a correlational study
performed in a naturalistic setting, which has screened for
psychopathology symptoms. Further longitudinal studies are
necessary to highlight the prevalence of psychiatric disorders in
a representative sample of patients including those with active
disease.
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